Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
; j4 F, k# i. u, G# T. A& b- l* o( ?8 j! d& M7 v# Z6 v5 b% S @; T
" O4 @2 v0 n' X' a4 R% E, wSub-category:
" d; f3 {" R; \( s7 }/ o1 ]Molecular Targets
7 f2 r% C1 o- M+ |# L) M3 t+ f" v' k. g! |/ A4 D7 P$ `
& e) Y/ s& H+ B. ?
Category:" R: Q( O2 {7 b* p1 Q
Tumor Biology 8 b) [, \$ ^( x" V9 O5 Q
+ _5 E5 ]9 k% |' @) S( `
0 n2 S) q# |: D% D# H# ?Meeting: H" h4 v* Z+ O
2011 ASCO Annual Meeting
! F K0 d, @8 B4 y3 c( a! k. T0 f3 b/ w
3 N1 j4 B# s1 x8 y
Session Type and Session Title:' w0 G4 y f! v
Poster Discussion Session, Tumor Biology
: J& x1 G& r; _& _$ D$ r% D& O( ]1 J& N5 X& v
0 D. o9 B# B" S. H% o3 W
Abstract No:! O0 L$ `9 i+ o3 `& w
10517 : S, d# K- y2 l# ], u1 Y% s
, ^" | i3 f5 N7 H0 E# f; p! D: W. {* g k: H6 o: f5 b
Citation:
! t \. C9 s7 y; `+ e3 e" @J Clin Oncol 29: 2011 (suppl; abstr 10517) % I, m9 o* \& n1 I, W" @
- D0 S5 V' @8 |; i0 z- G
d7 W" @ D! D: A0 E9 Z7 A3 `0 GAuthor(s):+ P: ~% G4 E$ B6 J7 A# c
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China : N4 x. }& s' `$ h, [2 ?. b
1 [+ M4 x' _5 h4 h* P
Q4 M4 s, \' d8 P% L$ ?/ |% E
l- ]5 R: i3 P N& p
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
3 q% s6 v0 j( A8 n: R- l
; Z; t" U0 h5 P9 [5 pAbstract Disclosures+ x; Z9 A. R" f0 I& E4 s+ ~! F. z
' C$ S' E! C$ u Z `Abstract:$ H$ U9 d. e) P: q
# N9 H, `; w! |0 V6 j9 i. l) X0 v6 H- |9 t* H& S" R" o
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
) B% l6 E5 N0 O, v# |+ t* A7 e5 Q$ s m2 }, b. Q( e$ p% d
7 a6 G ]4 ?% q/ Q4 {, {
|
11011102001537 )
显身卡
